98%
921
2 minutes
20
Objective: Understanding fluctuations in seizure severity within individuals is important for determining treatment outcomes and responses to therapy, as well as assessing novel treatments for epilepsy. Current methods for grading seizure severity rely on qualitative interpretations from patients and clinicians. Quantitative measures of seizure severity would complement existing approaches to electroencephalographic (EEG) monitoring, outcome monitoring, and seizure prediction. Therefore, we developed a library of quantitative EEG markers that assess the spread and intensity of abnormal electrical activity during and after seizures.
Methods: We analyzed intracranial EEG (iEEG) recordings of 1009 seizures from 63 patients. For each seizure, we computed 16 markers of seizure severity that capture the signal magnitude, spread, duration, and postictal suppression of seizures.
Results: Quantitative EEG markers of seizure severity distinguished focal versus subclinical seizures across patients. In individual patients, 53% had a moderate to large difference (rank sum , ) between focal and subclinical seizures in three or more markers. Circadian and longer term changes in severity were found for the majority of patients.
Significance: We demonstrate the feasibility of using quantitative iEEG markers to measure seizure severity. Our quantitative markers distinguish between seizure types and are therefore sensitive to established qualitative differences in seizure severity. Our results also suggest that seizure severity is modulated over different timescales. We envisage that our proposed seizure severity library will be expanded and updated in collaboration with the epilepsy research community to include more measures and modalities.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10952709 | PMC |
http://dx.doi.org/10.1111/epi.17525 | DOI Listing |
Neurol Sci
September 2025
Pediatric Neurosurgery Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Background: super-refractory status epilepticus (SRSE) is a rare and severe neurological condition associated with high mortality and significant long-term morbidity. In many cases, conventional medical treatments prove ineffective, with wide use of off-label therapies.
Methods: two researchers conducted a review of the medical records of subjects who had undergone VNS implantation in our tertiary Centre.
Congenital disorders of glycosylation (CDG) are a heterogeneous group of inherited metabolic diseases (IMD) characterized by defects in the synthesis and modification of glycoproteins and glycolipids. One of these disorders is ATP6AP1-CDG, a rare X-linked disease with approximately 30 cases reported so far. Symptoms associated with ATP6AP1-CDG include immunodeficiency, liver dysfunction, and neurological manifestations.
View Article and Find Full Text PDFJ Neural Eng
September 2025
University of Pennsylvania, 3400 Spruce Street, Philadelphia, Pennsylvania, 19104-6243, UNITED STATES.
New implantable and wearable devices hold great promise to help patients manage their seizure disorders. One proposed application is measuring the rate of interictal epileptiform discharges as a biomarker of medication levels and seizure risk. This study aims to determine whether interictal epileptiform spike rates (spikes) are independently associated with anti-seizure medication (ASM) levels and evaluate whether spike rates are a reliable biomarker for ASM levels.
View Article and Find Full Text PDFEpilepsy Behav
September 2025
Danone Research & Innovation, Uppsalalaan 12, 3584 CT Utrecht, the Netherlands. Electronic address:
Purpose: Ketogenic diet therapy (KDT) has been successfully used as an effective management option for drug resistant epilepsy (DRE) since the 1920 s. The ketogenic formulation studied here (KetoCal) is nutritionally complete, very high in fat, and low in carbohydrates and has played a crucial role in supporting the implementation of KDT for over twenty-five years. This scoping review aims to synthesise the existing literature regarding the safety, acceptability, and efficacy of the ketogenic formulation in supporting the management of DRE.
View Article and Find Full Text PDFJCI Insight
September 2025
Department of Physiology and Neurobiology, University of Connecticut, Storrs, United States of America.
Dravet syndrome (DS) is an early-onset epilepsy caused by loss of function mutations in the SCN1A gene, which encodes Nav1.1 channels that preferentially regulate activity of inhibitory neurons early in development. DS is associated with a high incidence of sudden unexpected death in epilepsy (SUDEP) by a mechanism that may involve respiratory failure.
View Article and Find Full Text PDF